fosforicum comp. 和酸的组合物. 和的组合物. 在患有神经衰竭的患者中:一种随机,双盲,安慰剂控制的临床试验
Juliane Hellhammer1, Luitgard Spitznagel-Schminke2, Rebecca Hufnagel2
1Contract Research Institute daacro, Trier, Germany.
Current medical research and opinion
|December 15, 2023
概括
这项研究研究了神经衰竭的Neurodoron (合金组合,KPC). 虽然KPC在整体上并不优越,但在后期分析中,KPC在减少易怒和紧张方面显示出好处,这表明它有可能缓解症状.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
- 精神病学是一个精神病学.
背景情况:
- 神经衰竭的特点是神经疲和感知到的压力.
- 持续寻找神经衰竭的有效和安全的治疗方案.
- 神经 (KPC) 是一种因其潜在的治疗作用而受到研究的产品.
研究的目的:
- 在患有神经衰竭的患者中,评估与安慰剂相比Neurodoron (KPC) 的疗效和安全性.
- 评估神经疲劳和感知压力的症状的减少.
- 为了确定6周治疗后一般健康状况的改善.
主要方法:
- 一个第四期,单中心,随机,双盲,安慰剂控制,并行组临床试验.
- 154名神经衰竭患者随机分配,接受KPC或安慰剂6周.
- 主要终点包括症状减轻和整体健康状况改善;次要分析探讨了特定症状变化.
主要成果:
- 在预先规定的分析中,对于初级疗效变量,KPC与安慰剂没有显著的优势.
- 与安慰剂相比,事后分析显示,KPC显著降低了易怒性 (p=0.020) 和紧张性 (p=0.045).
- 两组之间不良事件的发生率相似,没有严重的治疗相关事件.
结论:
- 神经 (KPC) 耐受性良好,并显示出良好的安全性.
- 虽然在初级终点上没有优势,但KPC在后期分析中显示了对特定的神经衰竭症状 (如易怒和紧张) 的潜在益处.
- KPC可以作为一种有益的治疗选择,用于缓解神经硬化症的症状.
相关概念视频
The Placebo Effect
6.2K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.2K
Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
153
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
153


